![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » GSK’s Hepatitis Drug Candidate Shows Promise
GSK’s Hepatitis Drug Candidate Shows Promise
In interim results from a mid-stage study, GlaxoSmithKline’s hepatitis drug candidate bepirovirsen showed the potential to suppress both the surface antigen and the virus of hepatitis B after 24 weeks, leading to “the possibility of functional cure,” the company said.
Bepirovirsen is an antisense oligonucleotide that targets the RNA that the hepatitis B virus uses to replicate itself in infected liver cells.
GSK said a phase 3 trial evaluating bepirovirsen as a monotherapy is slated to begin in the first half of 2023. The company is also exploring combinations of bepirovirsen and other therapeutic agents.
Chronic hepatitis B affects nearly 300 million people with approximately 900,000 patients dying each year from its associated complications.
Upcoming Events
-
18Jul
-
21Oct